Text Size

Evaluation of Vasopressin in the Vessels of Ovarian Neoplasms

This study has been completed.
Sponsor:
Information provided by:
Tripler Army Medical Center
ClinicalTrials.gov Identifier:
NCT00160472
First received: September 8, 2005
Last updated: February 25, 2010
Last verified: March 2004
History of Changes
  Purpose

This study will evaluate the expression of arginine vasopressin (AVP) by peptide and mRNA quantitation and also measurement of its V1 receptor mRNA, in the arteries and veins of ovarian malignant (cancerous) or benign (non-cancerous) tissue. The investigators will examine whether AVP protein and AVP and V1 receptor mRNA expression vary with respect to tumor histology, intratumoral vascularization and systemic blood pressure.


Condition Intervention
Ovarian Neoplasms
 Procedure: removal of ovarian vessels

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Bio-availability Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Diagnostic
Official Title: Evaluation of Vasopressin and Vasopressin Receptor Expression in the Arteries and Veins of Ovarian Neoplasms

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by Tripler Army Medical Center:

Primary Outcome Measures:
  • Compare the levels of AVP and the vasopressin V1 receptor expression in the arteries and veins of ovarian tissue found to be cancerous versus ovarian tissue found to be noncancerous
  • Correlate the expression of AVP and its V1 receptor to stage of ovarian neoplasms graded by histology assessment
  • Correlate the expression of AVP and its receptor to intratumoral vascularization through Doppler ultrasound and systemic blood pressure.

Estimated Enrollment: 110
Study Start Date: March 2004
Study Completion Date: January 2009
Primary Completion Date: January 2009 (Final data collection date for primary outcome measure)
  Show Detailed Description

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • All patients who have had gynecologic tissue removed for benign (noncancerous) or malignant (cancerous) indications.

Exclusion Criteria:

  • Patients who have a malignancy that is not a primary gynecologic malignancy.
  • Age less than 18
  • Males
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00160472

Locations
United States, Hawaii
Tripler Army Medical Center
Honolulu, Hawaii, United States, 96859
Sponsors and Collaborators
Department of Defense
Investigators
Principal Investigator: John H Farley, MD Uniformed Services Unievrsity of the Health Sciences
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00160472     History of Changes
Other Study ID Numbers: TAMC 3H04
Study First Received: September 8, 2005
Last Updated: February 25, 2010
Health Authority: United States: Federal Government

Keywords provided by Tripler Army Medical Center:
vasopressin
ovarian
neoplasm

Additional relevant MeSH terms:
Neoplasms
Ovarian Neoplasms
Endocrine Gland Neoplasms
Neoplasms by Site
Ovarian Diseases
Adnexal Diseases
Genital Diseases, Female
Genital Neoplasms, Female
Urogenital Neoplasms
Endocrine System Diseases
Gonadal Disorders
Vasopressins
 Arginine Vasopressin
Hemostatics
Coagulants
Hematologic Agents
Therapeutic Uses
Pharmacologic Actions
Vasoconstrictor Agents
Cardiovascular Agents
Antidiuretic Agents
Natriuretic Agents
Physiological Effects of Drugs

ClinicalTrials.gov processed this record on June 18, 2013